Amgen's Imdeltratra Reduces Death Risk in Extensive-Stage Small Cell Lung Cancer by 58%
AMGN AMGEN Inc
$439.26 -1.79%
View chart & analysis → - 1Adding Amgen's Imdeltratra to AstraZeneca's Imfinzi reduced the death risk for patients with extensive-stage small cell lung cancer by 58%.
- 2The combination therapy recorded a median overall survival of 21.1 months, an increase from the 12.7 months seen with AstraZeneca's drug alone.
- 3Imdeltratra recorded Q2 sales of $288 million, a 115% increase compared to the previous year.
So what's the key point?
Using Amgen's Imdeltratra alongside another drug reduced the death risk for lung cancer patients by 58%. Sales for this drug grew by 115% compared to last year.
Source CNBC · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.